Department of Health Promotion Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Front Endocrinol (Lausanne). 2021 Aug 12;12:711956. doi: 10.3389/fendo.2021.711956. eCollection 2021.
The association between non-alcoholic fatty liver disease (NAFLD) and thyroid hormones in euthyroid subjects is unclear. We investigated the relationship between thyroid function and the severity of hepatic steatosis and liver fibrosis in a large cohort of euthyroid Chinese adults.
A total of 3496 participants were enrolled. Liver ultrasonography was used to define the presence of NAFLD (n=2172) or the absence of NAFLD (n=1324). Anthropometric and biochemical measurements were made and thyroid function parameters including free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH) were measured. The severity of hepatic steatosis and liver stiffness was assessed by transient elastography.
Levels of FT3 were significantly higher in the severe NAFLD group and moderate NAFLD group than in the mild NAFLD group (5.18 ± 0.58 5.11 ± 0.57 4.98 ± 0.60 pmol/L, <0.001). Participants with F4 and F3 liver fibrosis had higher FT3 levels than those with F2 fibrosis (6.33 ± 0.39 5.29 ± 0.48 5.20 ± 0.50 pmol/L, <0.001). However, FT4 and TSH levels did not correlate with hepatic steatosis or liver fibrosis severity. In addition, the proportions of participants with NAFLD (46.0% 63.1% 73.3%, <0.001) and liver fibrosis (11.5% 18.6% 20.8%, <0.001) increased as FT3 levels increased. Logistic regression analysis showed that FT3 levels were positively associated with the severity of hepatic steatosis and liver fibrosis presence, even after adjustment for metabolic risk factors including BMI. In non-obese participants, the FT3 level was an independently risk factor for the severity of hepatic steatosis.
There are positive associations of FT3 levels with the severity of hepatic steatosis and the presence of liver fibrosis in NAFLD with euthyroidism.
非酒精性脂肪性肝病(NAFLD)与甲状腺激素在甲状腺功能正常的患者中的关系尚不清楚。我们在一个大型的甲状腺功能正常的中国成年人队列中研究了甲状腺功能与肝脂肪变性和肝纤维化严重程度之间的关系。
共纳入 3496 名参与者。使用肝脏超声来定义是否存在 NAFLD(n=2172)或不存在 NAFLD(n=1324)。测量人体测量和生化指标,并测量游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)等甲状腺功能参数。通过瞬时弹性成像评估肝脂肪变性和肝硬度的严重程度。
在严重 NAFLD 组和中度 NAFLD 组中,FT3 水平明显高于轻度 NAFLD 组(5.18±0.58 5.11±0.57 4.98±0.60 pmol/L,<0.001)。患有 F4 和 F3 纤维化的患者的 FT3 水平高于患有 F2 纤维化的患者(6.33±0.39 5.29±0.48 5.20±0.50 pmol/L,<0.001)。然而,FT4 和 TSH 水平与肝脂肪变性或肝纤维化严重程度无关。此外,随着 FT3 水平的升高,患有 NAFLD(46.0% 63.1% 73.3%,<0.001)和肝纤维化(11.5% 18.6% 20.8%,<0.001)的患者比例也随之增加。logistic 回归分析显示,即使在调整了包括 BMI 在内的代谢危险因素后,FT3 水平仍与肝脂肪变性和肝纤维化的严重程度呈正相关。在非肥胖患者中,FT3 水平是肝脂肪变性严重程度的独立危险因素。
在甲状腺功能正常的 NAFLD 患者中,FT3 水平与肝脂肪变性严重程度和肝纤维化的存在呈正相关。